Evaluation of Predictive Biomarkers in de Novo Multiple Myeloma on the Onset of Venous Thromboembolism, Its Impact on Clinical Outcome and Thromboprophylaxis (VESICOM)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patient affiliated to a social security regimen or beneficiary of the same
• Signed written informed consent form
• Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.
Locations
Other Locations
France
Hospices Civils de Lyon
RECRUITING
Lyon
CHU de Saint-Etienne
RECRUITING
Saint-etienne
Contact Information
Primary
Emilie Chalayer, MD
emilie.chalayer@chu-st-etienne.fr
04 77 91 70 00
Backup
Elisabeth Daguenet, PhD
elisabeth.daguenet@icloire.fr
Time Frame
Start Date: 2022-05-20
Estimated Completion Date: 2027-10-30
Participants
Target number of participants: 70
Treatments
Experimental: Patients with multiple myeloma
Adult patient, over 18 years old, with newly diagnosed multiple myeloma, indication of chemotherapy.
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de Saint Etienne